Mediolanum International Funds Ltd Sells 70,078 Shares of Corteva, Inc. $CTVA

Mediolanum International Funds Ltd lessened its position in shares of Corteva, Inc. (NYSE:CTVA) by 48.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,337 shares of the company’s stock after selling 70,078 shares during the period. Mediolanum International Funds Ltd’s holdings in Corteva were worth $6,166,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Corteva by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 80,536,951 shares of the company’s stock worth $5,398,392,000 after purchasing an additional 317,538 shares during the period. State Street Corp raised its position in shares of Corteva by 3.7% in the fourth quarter. State Street Corp now owns 36,570,876 shares of the company’s stock valued at $2,451,346,000 after purchasing an additional 1,290,071 shares during the period. Franklin Resources Inc. lifted its stake in shares of Corteva by 4.3% during the 4th quarter. Franklin Resources Inc. now owns 19,537,500 shares of the company’s stock valued at $1,309,599,000 after buying an additional 805,873 shares in the last quarter. Harris Associates L P boosted its holdings in Corteva by 168.1% in the 4th quarter. Harris Associates L P now owns 17,026,221 shares of the company’s stock worth $1,141,268,000 after buying an additional 10,675,052 shares during the period. Finally, Northern Trust Corp boosted its holdings in Corteva by 5.0% in the 4th quarter. Northern Trust Corp now owns 11,731,834 shares of the company’s stock worth $786,385,000 after buying an additional 562,550 shares during the period. 81.54% of the stock is owned by hedge funds and other institutional investors.

Corteva Price Performance

Corteva stock opened at $86.85 on Tuesday. Corteva, Inc. has a 52 week low of $60.53 and a 52 week high of $88.21. The business has a 50-day simple moving average of $80.94 and a 200 day simple moving average of $78.40. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07. The stock has a market cap of $58.09 billion, a price-to-earnings ratio of 51.09, a PEG ratio of 2.67 and a beta of 0.56.

Corteva (NYSE:CTVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.32. The firm had revenue of $4.91 billion for the quarter, compared to analysts’ expectations of $4.64 billion. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The company’s revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.13 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, research analysts forecast that Corteva, Inc. will post 3.72 earnings per share for the current fiscal year.

Corteva Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Monday, June 1st were paid a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Monday, June 1st. Corteva’s dividend payout ratio (DPR) is currently 42.35%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CTVA shares. UBS Group lowered their target price on shares of Corteva from $90.00 to $86.00 and set a “neutral” rating on the stock in a report on Tuesday, June 9th. Mizuho raised their price target on Corteva from $96.00 to $97.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. BNP Paribas Exane lifted their price target on Corteva from $74.00 to $77.00 in a research report on Wednesday, May 6th. Argus boosted their price objective on Corteva from $80.00 to $91.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, Morgan Stanley raised their target price on Corteva from $84.00 to $95.00 and gave the stock an “overweight” rating in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $89.62.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.